These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 19900449)

  • 1. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands.
    Capelle LG; Van Grieken NC; Lingsma HF; Steyerberg EW; Klokman WJ; Bruno MJ; Vasen HF; Kuipers EJ
    Gastroenterology; 2010 Feb; 138(2):487-92. PubMed ID: 19900449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risks of less common cancers in proven mutation carriers with lynch syndrome.
    Engel C; Loeffler M; Steinke V; Rahner N; Holinski-Feder E; Dietmaier W; Schackert HK; Goergens H; von Knebel Doeberitz M; Goecke TO; Schmiegel W; Buettner R; Moeslein G; Letteboer TG; Gómez García E; Hes FJ; Hoogerbrugge N; Menko FH; van Os TA; Sijmons RH; Wagner A; Kluijt I; Propping P; Vasen HF
    J Clin Oncol; 2012 Dec; 30(35):4409-15. PubMed ID: 23091106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome.
    Bonadona V; Bonaïti B; Olschwang S; Grandjouan S; Huiart L; Longy M; Guimbaud R; Buecher B; Bignon YJ; Caron O; Colas C; Noguès C; Lejeune-Dumoulin S; Olivier-Faivre L; Polycarpe-Osaer F; Nguyen TD; Desseigne F; Saurin JC; Berthet P; Leroux D; Duffour J; Manouvrier S; Frébourg T; Sobol H; Lasset C; Bonaïti-Pellié C;
    JAMA; 2011 Jun; 305(22):2304-10. PubMed ID: 21642682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families.
    Vasen HF; Stormorken A; Menko FH; Nagengast FM; Kleibeuker JH; Griffioen G; Taal BG; Moller P; Wijnen JT
    J Clin Oncol; 2001 Oct; 19(20):4074-80. PubMed ID: 11600610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for breast cancer as an integral part of Lynch syndrome.
    Buerki N; Gautier L; Kovac M; Marra G; Buser M; Mueller H; Heinimann K
    Genes Chromosomes Cancer; 2012 Jan; 51(1):83-91. PubMed ID: 22034109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term risk of colorectal cancer in individuals with lynch syndrome: a meta-analysis.
    Jenkins MA; Dowty JG; Ait Ouakrim D; Mathews JD; Hopper JL; Drouet Y; Lasset C; Bonadona V; Win AK
    J Clin Oncol; 2015 Feb; 33(4):326-31. PubMed ID: 25534380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome.
    Vasen HF; Abdirahman M; Brohet R; Langers AM; Kleibeuker JH; van Kouwen M; Koornstra JJ; Boot H; Cats A; Dekker E; Sanduleanu S; Poley JW; Hardwick JC; de Vos Tot Nederveen Cappel WH; van der Meulen-de Jong AE; Tan TG; Jacobs MA; Mohamed FL; de Boer SY; van de Meeberg PC; Verhulst ML; Salemans JM; van Bentem N; Westerveld BD; Vecht J; Nagengast FM
    Gastroenterology; 2010 Jun; 138(7):2300-6. PubMed ID: 20206180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer.
    Lu KH; Schorge JO; Rodabaugh KJ; Daniels MS; Sun CC; Soliman PT; White KG; Luthra R; Gershenson DM; Broaddus RR
    J Clin Oncol; 2007 Nov; 25(33):5158-64. PubMed ID: 17925543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of MLH1 and MSH2 mutations in Lynch syndrome.
    Balmaña J; Stockwell DH; Steyerberg EW; Stoffel EM; Deffenbaugh AM; Reid JE; Ward B; Scholl T; Hendrickson B; Tazelaar J; Burbidge LA; Syngal S
    JAMA; 2006 Sep; 296(12):1469-78. PubMed ID: 17003395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers.
    van der Post RS; Kiemeney LA; Ligtenberg MJ; Witjes JA; Hulsbergen-van de Kaa CA; Bodmer D; Schaap L; Kets CM; van Krieken JH; Hoogerbrugge N
    J Med Genet; 2010 Jul; 47(7):464-70. PubMed ID: 20591884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotype comparison of MLH1 and MSH2 mutation carriers in a cohort of 1,914 individuals undergoing clinical genetic testing in the United States.
    Kastrinos F; Stoffel EM; Balmaña J; Steyerberg EW; Mercado R; Syngal S
    Cancer Epidemiol Biomarkers Prev; 2008 Aug; 17(8):2044-51. PubMed ID: 18708397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lynch syndrome caused by MLH1 mutations is associated with an increased risk of breast cancer: a cohort study.
    Harkness EF; Barrow E; Newton K; Green K; Clancy T; Lalloo F; Hill J; Evans DG
    J Med Genet; 2015 Aug; 52(8):553-6. PubMed ID: 26101330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of gynecologic cancers in Danish hereditary non-polyposis colorectal cancer families.
    Boilesen AE; Bisgaard ML; Bernstein I
    Acta Obstet Gynecol Scand; 2008; 87(11):1129-35. PubMed ID: 18972272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Prediction Models for Lynch Syndrome Among Individuals With Colorectal Cancer.
    Kastrinos F; Ojha RP; Leenen C; Alvero C; Mercado RC; Balmaña J; Valenzuela I; Balaguer F; Green R; Lindor NM; Thibodeau SN; Newcomb P; Win AK; Jenkins M; Buchanan DD; Bertario L; Sala P; Hampel H; Syngal S; Steyerberg EW;
    J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26582061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spectrum of MLH1 and MSH2 mutations in Chilean families with suspected Lynch syndrome.
    Alvarez K; Hurtado C; Hevia MA; Wielandt AM; de la Fuente M; Church J; Carvallo P; López-Köstner F
    Dis Colon Rectum; 2010 Apr; 53(4):450-9. PubMed ID: 20305446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Excess of extracolonic non-endometrial multiple primary cancers in MSH2 germline mutation carriers over MLH1.
    Lin-Hurtubise KM; Yheulon CG; Gagliano RA; Lynch HT
    J Surg Oncol; 2013 Dec; 108(7):433-7. PubMed ID: 24122742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome.
    Watson P; Vasen HFA; Mecklin JP; Bernstein I; Aarnio M; Järvinen HJ; Myrhøj T; Sunde L; Wijnen JT; Lynch HT
    Int J Cancer; 2008 Jul; 123(2):444-449. PubMed ID: 18398828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of telomere dynamics in peripheral blood cells from patients with Lynch syndrome.
    Bozzao C; Lastella P; Ponz de Leon M; Pedroni M; Di Gregorio C; D'Ovidio FD; Resta N; Prete F; Guanti G; Stella A
    Cancer; 2011 Sep; 117(18):4325-35. PubMed ID: 21387278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members.
    Järvinen HJ; Renkonen-Sinisalo L; Aktán-Collán K; Peltomäki P; Aaltonen LA; Mecklin JP
    J Clin Oncol; 2009 Oct; 27(28):4793-7. PubMed ID: 19720893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients.
    Hampel H; Frankel W; Panescu J; Lockman J; Sotamaa K; Fix D; Comeras I; La Jeunesse J; Nakagawa H; Westman JA; Prior TW; Clendenning M; Penzone P; Lombardi J; Dunn P; Cohn DE; Copeland L; Eaton L; Fowler J; Lewandowski G; Vaccarello L; Bell J; Reid G; de la Chapelle A
    Cancer Res; 2006 Aug; 66(15):7810-7. PubMed ID: 16885385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.